News
- Author:
- Kelli Whitlock Burton
Publish date: January 10, 2023
Both adults and adolescents reported benefits from the diet, which is a less strict version of a traditional ketogenic diet.
News
- Author:
- Kelli Whitlock Burton
Publish date: January 3, 2023
More than 60% of patients with SPMS who received AHSCT were free from disability progression at 5 years.
News
- Author:
- Kelli Whitlock Burton
Publish date: January 3, 2023
Investigators suggest that prodromal Parkinson’s disease should be recognized as a distinct disease stage.
News
- Author:
- Kelli Whitlock Burton
Publish date: December 21, 2022
Although cluster headaches are often more prevalent in men, researchers found that multimorbidity rates were significantly higher in women.
News
- Author:
- Kelli Whitlock Burton
Publish date: December 21, 2022
About 60,000-90,000 individuals older than 45 years are estimated to be diagnosed with Parkinson’s disease each year.
News
- Author:
- Kelli Whitlock Burton
Publish date: December 1, 2022
The new framework is based on underlying biology of disease and acknowledges the different trajectories of individual patients.
News
- Author:
- Kelli Whitlock Burton
Publish date: November 9, 2022
The clear link between fine particulate matter exposure and increased risk emphasizes the need to address air pollution as a modifiable risk factor...
News
- Author:
- Kelli Whitlock Burton
Publish date: October 31, 2022
Dimethyl fumarate reduced the risk of a first acute or progressive event related to CNS demyelination by more than 80%, compared with placebo.
News
- Author:
- Kelli Whitlock Burton
Publish date: October 28, 2022
Preterm birth, spontaneous abortions, and major congenital anomalies were rare with anti-CD20 drugs ocrelizumab or natalizumab.
News
- Author:
- Kelli Whitlock Burton
Publish date: October 28, 2022
“The evidence for the use of the drug was never sufficient for clinicians to use it in their patients.”
News
- Author:
- Kelli Whitlock Burton
Publish date: October 28, 2022
AHSCT is substantially superior to fingolimod and marginally superior to natalizumab in reducing the risk of posttreatment relapses.
News
- Author:
- Kelli Whitlock Burton
Publish date: October 18, 2022
The double-blind, randomized clinical trial is the first to assess combining ketamine with a low-cost protective learning program.
News
- Author:
- Kelli Whitlock Burton
Publish date: October 15, 2022
Newborn screening, updated treatment guidelines, and treatment algorithms have changed what can be clinically done for patients with SMA, but still...
News
- Author:
- Kelli Whitlock Burton
Publish date: September 30, 2022
FDA officials in the meeting stressed the importance of considering unmet medical need in ALS in the panel’s decision-making process.
News
- Author:
- Kelli Whitlock Burton
Publish date: September 16, 2022
“If this is another burden that’s increased by COVID, this is something we’re really going to have to prepare for.”
